Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen's Q1 Revenues up 18 Percent on Organic Growth and Asian Demand

NEW YORK (GenomeWeb News) - Qiagen yesterday said first-quarter revenue rose 18 percent as R&D spending increased 13 percent and net income was up 13 percent.
 
Total receipts for the three months ended March 31, 2007, rose to $127.9 million from $108.7 million year over year.
 
Qiagen said that the strong sales were fuelled in part by an 11 percent increase in organic growth and a 2 percent contribution from acquisitions.
 
Sales of consumables made up 89 percent of the company's revenue for the quarter and added 15 percent of the growth. Instruments sales contributed 10 percent of total revenue and “other” revenue accounted for 1 percent.
 
The company saw a 48 percent increase in quarterly net sales to Asia, driven largely by demand in China, and by the company's expansion into Singapore and Korea.
 
Qiagen CEO Peer Schatz said the company introduced 13 new sample and assay products in the first quarter.
 
R&D spending increased to $11.5 million from $10.2 million year over year.
 
The company said profit increased to $19.9 million from $17.6 million in the year-ago period.
 
Qiagen said it had around $386.1 million in cash and equivalents and $98.9 million in short-term investments as of March 31.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.